Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation

Daniëlle Horst, Daphne Van Leeuwen, Nathan P. Croft, Malgorzata A. Garstka, Andrew D Hislop, Elisabeth Kremmer, Alan Bernard Rickinson, Emmanuel J H J Wiertz, Maaike E. Ressing

Research output: Contribution to journalArticleResearchpeer-review

Abstract

EBV persists for life in the human host while facing vigorous antiviral responses that are induced upon primary infection. This persistence supports the idea that herpesviruses have acquired dedicated functions to avoid immune elimination. The recently identified EBV gene product BNLF2a blocks TAP. As a result, reduced amounts of peptides are transported by TAP from the cytoplasm into the endoplasmic reticulum (ER) lumen for binding to newly synthesized HLA class I molecules. Thus, BNLF2a perturbs detection by cytotoxic T cells. The 60-aa-long BNLF2a protein prevents the binding of both peptides and ATP to TAP, yet further mechanistic insight is, to date, lacking. In this study, we report that EBV BNLF2a represents a membrane-associated protein that colocalizes with its target TAP in subcellular compartments, primarily the ER. In cells devoid of TAP, expression levels of BNLF2a protein are greatly diminished, while ER localization of the remaining BNLF2a is retained. For interactions of BNLF2a with the HLA class I peptide-loading complex, the presence of TAP2 is essential, whereas tapasin is dispensible. Importantly, we now show that in B cells supporting EBV lytic replication, the BNLF2a protein is expressed early in infection, colocalizing and associating with the peptide-loading complex. These results imply that, during productive EBV infection, BNLF2a contributes to TAP inhibition and surface HLA class I down-regulation. In this way, EBV BNLF2a-mediated evasion from HLA class I-restricted T cell immunity contributes to creating a window for undetected virus production.

Original languageEnglish
Pages (from-to)2313-2324
Number of pages12
JournalJournal of Immunology
Volume182
Issue number4
DOIs
Publication statusPublished - 15 Feb 2009
Externally publishedYes

Cite this

Horst, Daniëlle ; Van Leeuwen, Daphne ; Croft, Nathan P. ; Garstka, Malgorzata A. ; Hislop, Andrew D ; Kremmer, Elisabeth ; Rickinson, Alan Bernard ; Wiertz, Emmanuel J H J ; Ressing, Maaike E. / Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. In: Journal of Immunology. 2009 ; Vol. 182, No. 4. pp. 2313-2324.
@article{e592a9241b1342568635ed07b129d1b8,
title = "Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation",
abstract = "EBV persists for life in the human host while facing vigorous antiviral responses that are induced upon primary infection. This persistence supports the idea that herpesviruses have acquired dedicated functions to avoid immune elimination. The recently identified EBV gene product BNLF2a blocks TAP. As a result, reduced amounts of peptides are transported by TAP from the cytoplasm into the endoplasmic reticulum (ER) lumen for binding to newly synthesized HLA class I molecules. Thus, BNLF2a perturbs detection by cytotoxic T cells. The 60-aa-long BNLF2a protein prevents the binding of both peptides and ATP to TAP, yet further mechanistic insight is, to date, lacking. In this study, we report that EBV BNLF2a represents a membrane-associated protein that colocalizes with its target TAP in subcellular compartments, primarily the ER. In cells devoid of TAP, expression levels of BNLF2a protein are greatly diminished, while ER localization of the remaining BNLF2a is retained. For interactions of BNLF2a with the HLA class I peptide-loading complex, the presence of TAP2 is essential, whereas tapasin is dispensible. Importantly, we now show that in B cells supporting EBV lytic replication, the BNLF2a protein is expressed early in infection, colocalizing and associating with the peptide-loading complex. These results imply that, during productive EBV infection, BNLF2a contributes to TAP inhibition and surface HLA class I down-regulation. In this way, EBV BNLF2a-mediated evasion from HLA class I-restricted T cell immunity contributes to creating a window for undetected virus production.",
author = "Dani{\"e}lle Horst and {Van Leeuwen}, Daphne and Croft, {Nathan P.} and Garstka, {Malgorzata A.} and Hislop, {Andrew D} and Elisabeth Kremmer and Rickinson, {Alan Bernard} and Wiertz, {Emmanuel J H J} and Ressing, {Maaike E.}",
year = "2009",
month = "2",
day = "15",
doi = "10.4049/jimmunol.0803218",
language = "English",
volume = "182",
pages = "2313--2324",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. / Horst, Daniëlle; Van Leeuwen, Daphne; Croft, Nathan P.; Garstka, Malgorzata A.; Hislop, Andrew D; Kremmer, Elisabeth; Rickinson, Alan Bernard; Wiertz, Emmanuel J H J; Ressing, Maaike E.

In: Journal of Immunology, Vol. 182, No. 4, 15.02.2009, p. 2313-2324.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation

AU - Horst, Daniëlle

AU - Van Leeuwen, Daphne

AU - Croft, Nathan P.

AU - Garstka, Malgorzata A.

AU - Hislop, Andrew D

AU - Kremmer, Elisabeth

AU - Rickinson, Alan Bernard

AU - Wiertz, Emmanuel J H J

AU - Ressing, Maaike E.

PY - 2009/2/15

Y1 - 2009/2/15

N2 - EBV persists for life in the human host while facing vigorous antiviral responses that are induced upon primary infection. This persistence supports the idea that herpesviruses have acquired dedicated functions to avoid immune elimination. The recently identified EBV gene product BNLF2a blocks TAP. As a result, reduced amounts of peptides are transported by TAP from the cytoplasm into the endoplasmic reticulum (ER) lumen for binding to newly synthesized HLA class I molecules. Thus, BNLF2a perturbs detection by cytotoxic T cells. The 60-aa-long BNLF2a protein prevents the binding of both peptides and ATP to TAP, yet further mechanistic insight is, to date, lacking. In this study, we report that EBV BNLF2a represents a membrane-associated protein that colocalizes with its target TAP in subcellular compartments, primarily the ER. In cells devoid of TAP, expression levels of BNLF2a protein are greatly diminished, while ER localization of the remaining BNLF2a is retained. For interactions of BNLF2a with the HLA class I peptide-loading complex, the presence of TAP2 is essential, whereas tapasin is dispensible. Importantly, we now show that in B cells supporting EBV lytic replication, the BNLF2a protein is expressed early in infection, colocalizing and associating with the peptide-loading complex. These results imply that, during productive EBV infection, BNLF2a contributes to TAP inhibition and surface HLA class I down-regulation. In this way, EBV BNLF2a-mediated evasion from HLA class I-restricted T cell immunity contributes to creating a window for undetected virus production.

AB - EBV persists for life in the human host while facing vigorous antiviral responses that are induced upon primary infection. This persistence supports the idea that herpesviruses have acquired dedicated functions to avoid immune elimination. The recently identified EBV gene product BNLF2a blocks TAP. As a result, reduced amounts of peptides are transported by TAP from the cytoplasm into the endoplasmic reticulum (ER) lumen for binding to newly synthesized HLA class I molecules. Thus, BNLF2a perturbs detection by cytotoxic T cells. The 60-aa-long BNLF2a protein prevents the binding of both peptides and ATP to TAP, yet further mechanistic insight is, to date, lacking. In this study, we report that EBV BNLF2a represents a membrane-associated protein that colocalizes with its target TAP in subcellular compartments, primarily the ER. In cells devoid of TAP, expression levels of BNLF2a protein are greatly diminished, while ER localization of the remaining BNLF2a is retained. For interactions of BNLF2a with the HLA class I peptide-loading complex, the presence of TAP2 is essential, whereas tapasin is dispensible. Importantly, we now show that in B cells supporting EBV lytic replication, the BNLF2a protein is expressed early in infection, colocalizing and associating with the peptide-loading complex. These results imply that, during productive EBV infection, BNLF2a contributes to TAP inhibition and surface HLA class I down-regulation. In this way, EBV BNLF2a-mediated evasion from HLA class I-restricted T cell immunity contributes to creating a window for undetected virus production.

UR - http://www.scopus.com/inward/record.url?scp=61449138716&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0803218

DO - 10.4049/jimmunol.0803218

M3 - Article

VL - 182

SP - 2313

EP - 2324

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -